Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Significant Increase in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 273,000 shares, a growth of 134.9% from the December 31st total of 116,200 shares. Based on an average trading volume of 242,400 shares, the short-interest ratio is currently 1.1 days. Approximately 6.3% of the shares of the stock are sold short.

Vivos Therapeutics Price Performance

VVOS traded up $0.04 during midday trading on Friday, reaching $3.97. 114,554 shares of the company’s stock were exchanged, compared to its average volume of 292,809. Vivos Therapeutics has a 1-year low of $1.91 and a 1-year high of $7.74. The stock has a market capitalization of $23.38 million, a PE ratio of -0.70 and a beta of 7.51. The business’s 50-day moving average price is $4.49 and its 200 day moving average price is $3.30.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Alliance Global Partners lowered their target price on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Ascendiant Capital Markets reiterated a “buy” rating and set a $6.60 target price on shares of Vivos Therapeutics in a research report on Wednesday, November 20th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.